Synergetics USA (SURG) 4.44 $SURG
Allscripts Sunrise EHR: IHMC's Choice for Flagship Hospital - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 1:57PM CST
Allscripts recently announced that its Sunrise Acute Care has been selected by Texas-based International Hospital Management Corp. (IHMC).
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), MDRX: 11.80 (+0.04), SURG: 4.44 (-0.02)
Bioanalytical Systems' Breakeven Q1 Earnings, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 9:00AM CST
Bioanalytical Systems (BASI) reported adjusted breakeven earnings per share (EPS) in the first quarter of fiscal 2015, which was lower by 3 cents on a year-over-year basis
ABMD: 60.39 (+0.46), BASI: 2.06 (+0.18), INGN: 33.53 (+2.32), SURG: 4.44 (-0.02)
Alere (ALR) Disappoints; Misses on Earnings, Revenues in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:44AM CST
Alere Inc. (ALR) reported disappointing fourth-quarter 2014 results with both its top and bottom line missing the Zacks Consensus Estimate.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), ALR: 43.40 (-0.40), SURG: 4.44 (-0.02)
Acadia Healthcare Posts In-Line Q4 Earnings, Revenue Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 8:54AM CST
Acadia Healthcare Company (ACHC) reported fourth-quarter 2014 adjusted earnings (EPS) of 46 cents per share, which surged an impressive 58.6% year over year.
ACHC: 63.20 (-0.45), ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), SURG: 4.44 (-0.02)
Invacare (IVC) Reports Narrower Q4 Loss, Beats on Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:29AM CST
Invacare Corp. (IVC) reported adjusted loss of 12 cents per share in the fourth quarter of 2014, which was narrower than the Zacks Consensus Estimate of a loss of 23 cents
ABMD: 60.39 (+0.46), IVC: 17.13 (+0.15), INGN: 33.53 (+2.32), SURG: 4.44 (-0.02)
Affymetrix (AFFX) Earnings, Revenues Outshine Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 8:56AM CST
Affymetrix Inc. (AFFX) reported adjusted earnings per share (EPS) of 9 cents in the fourth quarter of 2014, which managed to beat the Zacks Consensus Estimate by a couple of cents
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), AFFX: 11.45 (+0.02), SURG: 4.44 (-0.02)
Techne Q2 Earnings, Revenues Miss Estimates but Grow Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 8:56AM CST
Techne Corp. (TECH) reported adjusted earnings (EPS) of 82 cents per share in the second quarter of fiscal 2015, which missed the Zacks Consensus Estimate by 4 cents
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), TECH: 94.61 (+1.83), SURG: 4.44 (-0.02)
Pacific Biosciences Posts Q4 Loss as Expected, Shares Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 8:28AM CST
Pacific Biosciences of California Inc. (PACB) plunged 5.2% (43 cents) to $7.90 in after-hours trading on the heels of disappointing fourth-quarter results.
ABMD: 60.39 (+0.46), PACB: 6.96 (-0.06), INGN: 33.53 (+2.32), SURG: 4.44 (-0.02)
Intuitive Surgical Announces $1B Share Buyback Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 4:57PM CST
Intuitive Surgical Inc (ISRG) recently announced a new share buyback program worth $1 billion.
ISRG: 510.73 (+3.02), ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), SURG: 4.44 (-0.02)
Wright Medical (WMGI) Gets Second Request from FTC - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 3:20PM CST
Wright Medical Group, Inc. (WMGI) recently announced that it has received a Request for Additional Information and Documentary Material (commonly known as a Second Request) from the Federal Trade Commission ("FTC"
.
WMGI: 25.68 (+0.17), INGN: 33.53 (+2.32), TRNX: 25.32 (+0.12), SURG: 4.44 (-0.02)
Cerner (CERN) Acquires Siemens Health Services Operations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 3:10PM CST
Cerner Corp (CERN) completed the acquisition of Siemens Health Services on Feb 2.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), CERN: 70.98 (+1.15), SURG: 4.44 (-0.02)
Luminex (LMNX) Q4 Earnings Top, Revenues Meet Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 8:30AM CST
Luminex Corporation (LMNX) reported fourth-quarter 2014 adjusted earnings per share (EPS) of 15 cents, which managed to beat the Zacks Consensus Estimate by 3 cents. However, adjusted EPS fell by a penny on a year-over-year basis
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02), SURG: 4.44 (-0.02)
Luminex Gets Health Canada Approval for Genotyping Assay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 5:35PM CST
Developer and seller of proprietary biological testing technologies, Luminex Corp (LMNX), recently received Health Canada approval for its genotyping assay, xTAG CYP2D6 Kit v3.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02), SURG: 4.44 (-0.02)
Abiomed: A Strong Buy on Impressive Q3, Estimate Revision - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 4:30PM CST
We believe that Abiomed Inc.'s (ABMD) strong third-quarter fiscal 2015 results, raised fiscal 2015 guidance and the recent FDA HDE approval for its Impella RP System are the primary factors justifying the upgrade.
ABMD: 60.39 (+0.46), BEAT: 10.36 (+0.20), INGN: 33.53 (+2.32), SURG: 4.44 (-0.02)
AngioDynamics Celerity System Gets Expanded FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 3:00PM CST
Per the latest approval, clinicians can do away with the follow-up X-ray when AngioDynamics Inc.'s (ANGO) Celerity system is used to assist in the positioning of PICCs in adult patients.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), ANGO: 18.78 (+0.18), SURG: 4.44 (-0.02)
FDA OKs DexCom Glucose Monitoring System with Share App - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 3:35PM CST
Developer of continuous glucose monitoring systems, DexCom, Inc. (DXCM), recently received the FDA approval for its Dexcom G4 PLATINUM Continuous Glucose Monitoring System with Share.
DXCM: 62.68 (+0.74), INGN: 33.53 (+2.32), AAPL: 127.08 (+0.62), SURG: 4.44 (-0.02)
Abiomed Q3 Earnings Impress; Impella RP Gets FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 10:30AM CST
Per Abiomed Inc.'s (ABMD) third-quarter results, both earnings and revenues crushed their respective Zacks Consensus Estimates and also showed remarkable year-over-year growth.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), EW: 134.23 (+1.89), SURG: 4.44 (-0.02)
Accuray (ARAY) Q2 Loss Wider than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 10:20AM CST
Radiation oncology company, Accuray Inc. (ARAY), reported a loss of 13 cents per share in the second quarter of fiscal 2015, wider than the Zacks Consensus Estimate of a loss of 8 cents and the year-ago loss of 7 cents per share.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), ARAY: 8.00 (+0.24), SURG: 4.44 (-0.02)
Quality Systems Beats Q3 Earnings on Revenue Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 1:57PM CST
Quality Systems Inc (QSII) reported impressive third-quarter 2015 financial numbers
INGN: 33.53 (+2.32), PDCO: 50.65 (-0.16), QSII: 17.04 (+0.38), SURG: 4.44 (-0.02)
Falling Earnings Estimates Signal Weakness Ahead for Accuray (ARAY) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 7:32AM CST
Accuray has an unfavorable Zacks Rank and the stock has been witnessing a significant price decline and negative earnings estimate revisions
ARAY: 8.00 (+0.24), SURG: 4.44 (-0.02)
Allscripts Sunrise EHR: IHMC's Choice for Flagship Hospital - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 1:57PM CST
Allscripts recently announced that its Sunrise Acute Care has been selected by Texas-based International Hospital Management Corp. (IHMC).
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), MDRX: 11.80 (+0.04), SURG: 4.44 (-0.02)
Bioanalytical Systems' Breakeven Q1 Earnings, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 9:00AM CST
Bioanalytical Systems (BASI) reported adjusted breakeven earnings per share (EPS) in the first quarter of fiscal 2015, which was lower by 3 cents on a year-over-year basis
ABMD: 60.39 (+0.46), BASI: 2.06 (+0.18), INGN: 33.53 (+2.32), SURG: 4.44 (-0.02)
Alere (ALR) Disappoints; Misses on Earnings, Revenues in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:44AM CST
Alere Inc. (ALR) reported disappointing fourth-quarter 2014 results with both its top and bottom line missing the Zacks Consensus Estimate.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), ALR: 43.40 (-0.40), SURG: 4.44 (-0.02)
Acadia Healthcare Posts In-Line Q4 Earnings, Revenue Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 8:54AM CST
Acadia Healthcare Company (ACHC) reported fourth-quarter 2014 adjusted earnings (EPS) of 46 cents per share, which surged an impressive 58.6% year over year.
ACHC: 63.20 (-0.45), ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), SURG: 4.44 (-0.02)
Invacare (IVC) Reports Narrower Q4 Loss, Beats on Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:29AM CST
Invacare Corp. (IVC) reported adjusted loss of 12 cents per share in the fourth quarter of 2014, which was narrower than the Zacks Consensus Estimate of a loss of 23 cents
ABMD: 60.39 (+0.46), IVC: 17.13 (+0.15), INGN: 33.53 (+2.32), SURG: 4.44 (-0.02)
Affymetrix (AFFX) Earnings, Revenues Outshine Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 8:56AM CST
Affymetrix Inc. (AFFX) reported adjusted earnings per share (EPS) of 9 cents in the fourth quarter of 2014, which managed to beat the Zacks Consensus Estimate by a couple of cents
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), AFFX: 11.45 (+0.02), SURG: 4.44 (-0.02)
Techne Q2 Earnings, Revenues Miss Estimates but Grow Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 8:56AM CST
Techne Corp. (TECH) reported adjusted earnings (EPS) of 82 cents per share in the second quarter of fiscal 2015, which missed the Zacks Consensus Estimate by 4 cents
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), TECH: 94.61 (+1.83), SURG: 4.44 (-0.02)
Pacific Biosciences Posts Q4 Loss as Expected, Shares Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 8:28AM CST
Pacific Biosciences of California Inc. (PACB) plunged 5.2% (43 cents) to $7.90 in after-hours trading on the heels of disappointing fourth-quarter results.
ABMD: 60.39 (+0.46), PACB: 6.96 (-0.06), INGN: 33.53 (+2.32), SURG: 4.44 (-0.02)
Intuitive Surgical Announces $1B Share Buyback Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 4:57PM CST
Intuitive Surgical Inc (ISRG) recently announced a new share buyback program worth $1 billion.
ISRG: 510.73 (+3.02), ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), SURG: 4.44 (-0.02)
Wright Medical (WMGI) Gets Second Request from FTC - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 3:20PM CST
Wright Medical Group, Inc. (WMGI) recently announced that it has received a Request for Additional Information and Documentary Material (commonly known as a Second Request) from the Federal Trade Commission ("FTC"
. WMGI: 25.68 (+0.17), INGN: 33.53 (+2.32), TRNX: 25.32 (+0.12), SURG: 4.44 (-0.02)
Cerner (CERN) Acquires Siemens Health Services Operations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 3:10PM CST
Cerner Corp (CERN) completed the acquisition of Siemens Health Services on Feb 2.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), CERN: 70.98 (+1.15), SURG: 4.44 (-0.02)
Luminex (LMNX) Q4 Earnings Top, Revenues Meet Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 8:30AM CST
Luminex Corporation (LMNX) reported fourth-quarter 2014 adjusted earnings per share (EPS) of 15 cents, which managed to beat the Zacks Consensus Estimate by 3 cents. However, adjusted EPS fell by a penny on a year-over-year basis
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02), SURG: 4.44 (-0.02)
Luminex Gets Health Canada Approval for Genotyping Assay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 5:35PM CST
Developer and seller of proprietary biological testing technologies, Luminex Corp (LMNX), recently received Health Canada approval for its genotyping assay, xTAG CYP2D6 Kit v3.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02), SURG: 4.44 (-0.02)
Abiomed: A Strong Buy on Impressive Q3, Estimate Revision - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 4:30PM CST
We believe that Abiomed Inc.'s (ABMD) strong third-quarter fiscal 2015 results, raised fiscal 2015 guidance and the recent FDA HDE approval for its Impella RP System are the primary factors justifying the upgrade.
ABMD: 60.39 (+0.46), BEAT: 10.36 (+0.20), INGN: 33.53 (+2.32), SURG: 4.44 (-0.02)
AngioDynamics Celerity System Gets Expanded FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 3:00PM CST
Per the latest approval, clinicians can do away with the follow-up X-ray when AngioDynamics Inc.'s (ANGO) Celerity system is used to assist in the positioning of PICCs in adult patients.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), ANGO: 18.78 (+0.18), SURG: 4.44 (-0.02)
FDA OKs DexCom Glucose Monitoring System with Share App - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 3:35PM CST
Developer of continuous glucose monitoring systems, DexCom, Inc. (DXCM), recently received the FDA approval for its Dexcom G4 PLATINUM Continuous Glucose Monitoring System with Share.
DXCM: 62.68 (+0.74), INGN: 33.53 (+2.32), AAPL: 127.08 (+0.62), SURG: 4.44 (-0.02)
Abiomed Q3 Earnings Impress; Impella RP Gets FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 10:30AM CST
Per Abiomed Inc.'s (ABMD) third-quarter results, both earnings and revenues crushed their respective Zacks Consensus Estimates and also showed remarkable year-over-year growth.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), EW: 134.23 (+1.89), SURG: 4.44 (-0.02)
Accuray (ARAY) Q2 Loss Wider than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 10:20AM CST
Radiation oncology company, Accuray Inc. (ARAY), reported a loss of 13 cents per share in the second quarter of fiscal 2015, wider than the Zacks Consensus Estimate of a loss of 8 cents and the year-ago loss of 7 cents per share.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), ARAY: 8.00 (+0.24), SURG: 4.44 (-0.02)
Quality Systems Beats Q3 Earnings on Revenue Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 1:57PM CST
Quality Systems Inc (QSII) reported impressive third-quarter 2015 financial numbers
INGN: 33.53 (+2.32), PDCO: 50.65 (-0.16), QSII: 17.04 (+0.38), SURG: 4.44 (-0.02)
Falling Earnings Estimates Signal Weakness Ahead for Accuray (ARAY) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 7:32AM CST
Accuray has an unfavorable Zacks Rank and the stock has been witnessing a significant price decline and negative earnings estimate revisions
ARAY: 8.00 (+0.24), SURG: 4.44 (-0.02)
